Lupin gets USFDA nod for Meclizine Hydrochloride Tablets USP

Lupin Limited announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application of Meclizine Hydrochloride Tablets USP.

The Meclizine Hydrochloride Tablets 12.5 mg, 25 mg, and 50 mg, to market a generic equivalent of Antivert Tablets, 12.5 mg, 25 mg, and 50 mg, of Casper Pharma LLC will be manufactured at Lupin’s facility in Goa. Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the US.